Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Spring;1(1):154-164.
doi: 10.20411/pai.v1i1.133.

A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?

Michael M Lederman  1 , Paula M Cannon  2 , Judith S Currier  3 , Carl H June  4 , Hans Peter Kiem  5 , Daniel R Kuritzkes  5 , Sharon R Lewin  6 , David M Margolis  7 , Joseph M McCune  8 , John W Mellors  9 , Timothy W Schacker  10 , Rafick P Sekaly  1 , Pablo Tebas  4 , Bruce D Walker  11 , Daniel C Douek  12
Affiliations

A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?

Michael M Lederman et al. Pathog Immun. 2016 Spring.

Abstract

With the advent and stunning success of combination antiretroviral therapy (ART) to prolong and improve quality of life for persons with HIV infection, HIV research has been afforded the opportunity to pivot towards studies aimed at finding "a cure." The mere idea that cure of HIV might be possible has energized researchers and the community towards achieving this goal. Funding agencies, both governmental and private, have targeted HIV cure as a high priority; many in the field have responded to these initiatives and the cure research agenda is robust. In this "salon" two editors of Pathogens and Immunity, Michael Lederman and Daniel Douek ask whether curing HIV is a realistic, scalable objective. We start with an overview perspective and have asked a number of prominent HIV researchers to add to the discussion.

Keywords: Berlin Patient; CCR5; HIV; cure; elite controller; eradication; functional cure; inflammation; latency; procoagulant; reservoir.

PubMed Disclaimer

References

    1. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8. PubMed PMID: . doi: 10.1056/NEJMoa0802905 - DOI - PubMed
    1. Hutter G. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N Engl J Med. 2014;371(25):2437–8. PubMed PMID: . doi: 10.1056/NEJMc1412279#SA1 - DOI - PubMed
    1. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101(7):2711–20. PubMed PMID: . doi: 10.1182/blood-2002-07-2103 - DOI - PubMed
    1. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350–4. PubMed PMID: . doi: 10.1038/nature05115 - DOI - PubMed
    1. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014;111(6):2307–12. PubMed PMID: Pubmed Central PMCID: . doi: 10.1073/pnas.1318249111 - DOI - PMC - PubMed